Trial Profile
A Retrospective,Cohort study to compare the stroke, bleeding, and mortality risks in non-valvular atrial fibrillation patients treated with Dabigatran or Rivaroxaban
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- 15 Nov 2016 New trial record